(NasdaqGM:ONEW), Fiscal First Quarter 2025 Highlights Revenue increased 3% to $376 million Same-store sales increased 4%, including an increase in units sold Gross profit margin of 22.4%, impacted by exiting brands GAAP net loss of $14 million, or $(0.81) per diluted share and adjusted diluted loss per share1 of $(0.54) Adjusted EBITDA1 of $2 million […]
(NASDAQ:BEEM), SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, announced today that it is expanding its sales network in Europe with the addition of three new business partners: Seltis Glass Design S.R.L. for the
(NASDAQ:CNOB), ENGLEWOOD CLIFFS, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $18.9 million for the fourth quarter of 2024 compared with $15.7 million for the third quarter of 2024 and $17.8
(NYSE:KEX), Fourth quarter 2024 GAAP earnings per share of $0.74, and fourth quarter 2024 adjusted earnings per share(1) of $1.29. Fourth quarter 2024 inland marine term contracts repriced higher in the 6-9% range year-over-year. Kirby repurchased 286,697 shares at an average price of $116.16 for $33.3 million and reduced debt balances by $105 million in
(NASDAQ:VIGL), WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30
(NASDAQ:HOOK),(LSE – AIM:HOOK), HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected
(NASDAQ:ALGM), MANCHESTER, N.H., Jan. 30, 2025 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its third quarter ended December 27, 2024. “We delivered on our commitments with third quarter sales
(NasdaqGM:TNGX), BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID
(NASDAQ:DNTH), NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences
(TSX-V:ABI),(OTC US:ABMBF),(Other OTC:ABMBF), ROUYN-NORANDA, Quebec, Jan. 30, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture: ABI) (OTCQB : ABMBF) is pleased to announce the first assay results from its most recent drilling campaign currently underway on its Flordin property (100% ABI) in the Lebel-sur-Quevillon area. Highlights: The Adam mineralized zone